Oric Pharmaceuticals, Inc. Financials
This page shows Oric Pharmaceuticals, Inc. (ORIC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing is sustaining a research-first operating model while reported balance-sheet growth is not showing up as cash.
FY2025 brought financing inflows of$245.3M , pushing total assets to$408.9M . Yet cash finished at only$45.7M , so the stronger balance sheet mainly reflects capital that was redeployed into operations and investments rather than retained as liquidity.
R&D spending of
ROE moved from
Financial Health Signals
Oric Pharmaceuticals, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Oric Pharmaceuticals, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Oric Pharmaceuticals, Inc. reported a net loss of $129.5M while operations used $111.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Oric Pharmaceuticals, Inc.'s EBITDA was -$141.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. That is unchanged from the prior year.
Oric Pharmaceuticals, Inc. reported -$129.5M in net income in fiscal year 2025. This represents a decrease of 1.3% from the prior year.
Oric Pharmaceuticals, Inc. earned -$1.47 per diluted share (EPS) in fiscal year 2025. This represents an increase of 19.7% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Oric Pharmaceuticals, Inc. recorded an outflow of $111.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 1.9% from the prior year.
Oric Pharmaceuticals, Inc. held $45.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Oric Pharmaceuticals, Inc.'s ROE was -33.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 18.9 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Oric Pharmaceuticals, Inc. invested $109.8M in research and development in fiscal year 2025. This represents a decrease of 3.7% from the prior year.
Oric Pharmaceuticals, Inc. invested $712K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 40.1% from the prior year.
Not reported for fiscal year 2025.
ORIC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $109.8M-3.7% | $114.1M+33.9% | $85.2M+38.1% | $61.7M+8.5% | $56.9M+58.3% | $35.9M+57.2% | $22.8M+20.1% | $19.0M |
| SG&A Expenses | N/A | $33.2M+15.1% | $28.8M+12.6% | $25.6M+2.1% | $25.1M+14.0% | $22.0M+64.0% | $13.4M+134.4% | $5.7M+71.2% | $3.3M |
| Operating Income | N/A | -$143.0M-0.1% | -$142.9M-29.0% | -$110.8M-20.7% | -$91.8M-16.4% | -$78.9M-6.3% | -$74.2M-159.7% | -$28.6M-27.7% | -$22.4M |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | N/A | -$129.5M-1.3% | -$127.8M-27.0% | -$100.7M-13.0% | -$89.1M-13.2% | -$78.7M-6.8% | -$73.7M-174.2% | -$26.9M-25.8% | -$21.4M |
| EPS (Diluted) | — | -$1.47+19.7% | -$1.83+6.6% | -$1.96+12.9% | -$2.25-8.7% | -$2.07 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ORIC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $408.9M+49.2% | $274.1M+8.8% | $252.0M+2.0% | $247.2M-17.2% | $298.6M-0.1% | $299.0M+217.8% | $94.1M | N/A |
| Current Assets | $288.5M+10.0% | $262.3M+23.4% | $212.6M+1.0% | $210.5M-12.5% | $240.5M-18.9% | $296.7M+229.7% | $90.0M | N/A |
| Cash & Equivalents | $45.7M-23.1% | $59.4M+154.0% | $23.4M-65.0% | $66.8M-70.4% | $226.0M+188.1% | $78.4M-12.0% | $89.2M+109.1% | $42.6M |
| Total Liabilities | $24.5M-20.9% | $31.0M+11.1% | $27.9M+12.5% | $24.8M-3.3% | $25.7M+178.3% | $9.2M-95.0% | $184.2M | N/A |
| Current Liabilities | $20.4M-17.8% | $24.8M+21.4% | $20.5M+32.9% | $15.4M+1.6% | $15.2M+68.3% | $9.0M+68.1% | $5.4M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | $10.5M+1650.0% | $600K | N/A | N/A |
| Total Equity | $384.4M+58.1% | $243.1M+8.5% | $224.1M+0.8% | $222.4M-18.5% | $273.0M-5.8% | $289.8M+421.7% | -$90.1M-39.8% | -$64.4M |
| Retained Earnings | -$692.2M-23.0% | -$562.8M-29.4% | -$434.9M-30.1% | -$334.2M-36.4% | -$245.1M-47.3% | -$166.4M-79.5% | -$92.7M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
ORIC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$111.6M | -$111.0M+1.5% | -$112.7M-31.5% | -$85.7M-14.0% | -$75.1M-26.2% | -$59.5M-31.5% | -$45.3M-92.4% | -$23.5M-13.8% | -$20.7M |
| Capital Expenditures | $620K | $712K-40.1% | $1.2M+39.9% | $849K-59.1% | $2.1M+121.3% | $939K+40.8% | $667K-13.2% | $768K+46.3% | $525K |
| Free Cash Flow | -$112.3M | -$111.7M+1.9% | -$113.8M-31.6% | -$86.5M-12.1% | -$77.2M-27.7% | -$60.5M-31.7% | -$45.9M-89.0% | -$24.3M-14.6% | -$21.2M |
| Investing Cash Flow | -$99.7M | -$148.0M-768.7% | $22.1M+151.0% | -$43.4M+60.3% | -$109.2M-169.0% | $158.4M+173.4% | -$216.0M-28019.7% | -$768K-51.2% | -$508K |
| Financing Cash Flow | $172.9M | $245.3M+93.8% | $126.5M+47.7% | $85.7M+239.6% | $25.2M-48.7% | $49.1M-80.4% | $250.5M+253.7% | $70.8M+86.3% | $38.0M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ORIC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -33.7%+18.9pp | -52.6%-7.7pp | -44.9%-4.9pp | -40.1%-11.2pp | -28.8%-3.4pp | -25.4% | N/A | N/A |
| Return on Assets | -31.7%+15.0pp | -46.6%-6.7pp | -40.0%-3.9pp | -36.1%-9.7pp | -26.4%-1.7pp | -24.6%+3.9pp | -28.6% | N/A |
| Current Ratio | 14.13+3.6x | 10.55+0.2x | 10.39-3.3x | 13.68-2.2x | 15.88-17.1x | 32.96+16.1x | 16.81 | N/A |
| Debt-to-Equity | 0.06-0.1x | 0.130.0x | 0.120.0x | 0.11+0.1x | 0.040.0x | 0.00 | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Oric Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
Is Oric Pharmaceuticals, Inc. profitable?
No, Oric Pharmaceuticals, Inc. (ORIC) reported a net income of -$129.5M in fiscal year 2025.
What is Oric Pharmaceuticals, Inc.'s EBITDA?
Oric Pharmaceuticals, Inc. (ORIC) had EBITDA of -$141.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Oric Pharmaceuticals, Inc.'s return on equity (ROE)?
Oric Pharmaceuticals, Inc. (ORIC) has a return on equity of -33.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Oric Pharmaceuticals, Inc.'s free cash flow?
Oric Pharmaceuticals, Inc. (ORIC) recorded an outflow of $111.7M in free cash flow during fiscal year 2025. This represents a 1.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Oric Pharmaceuticals, Inc.'s operating cash flow?
Oric Pharmaceuticals, Inc. (ORIC) recorded an outflow of $111.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Oric Pharmaceuticals, Inc.'s total assets?
Oric Pharmaceuticals, Inc. (ORIC) had $408.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Oric Pharmaceuticals, Inc.'s capital expenditures?
Oric Pharmaceuticals, Inc. (ORIC) invested $712K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Oric Pharmaceuticals, Inc. spend on research and development?
Oric Pharmaceuticals, Inc. (ORIC) invested $109.8M in research and development during fiscal year 2025.
What is Oric Pharmaceuticals, Inc.'s current ratio?
Oric Pharmaceuticals, Inc. (ORIC) had a current ratio of 14.13 as of fiscal year 2025, which is generally considered healthy.
What is Oric Pharmaceuticals, Inc.'s debt-to-equity ratio?
Oric Pharmaceuticals, Inc. (ORIC) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Oric Pharmaceuticals, Inc.'s return on assets (ROA)?
Oric Pharmaceuticals, Inc. (ORIC) had a return on assets of -31.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Oric Pharmaceuticals, Inc.'s cash runway?
Based on fiscal year 2025 data, Oric Pharmaceuticals, Inc. (ORIC) had $45.7M in cash against an annual operating cash burn of $111.0M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Oric Pharmaceuticals, Inc.'s Piotroski F-Score?
Oric Pharmaceuticals, Inc. (ORIC) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Oric Pharmaceuticals, Inc.'s earnings high quality?
Oric Pharmaceuticals, Inc. (ORIC) reported a net loss of $129.5M while operations used $111.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.